RA0081

antibody from Oursmab

Targeting: CD274 B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0081

Provider

Oursmab

Product name

Adebrelimab (Biosimilar Reference Antibody) (CD274)

Antibody type

Monoclonal

Description

Adebrelimab is a fully human IgG4 monoclonal antibody targeting the programmed cell death ligand 1 (PD-L1). It functions as an immune checkpoint inhibitor by specifically binding to PD-L1, thereby blocking its interaction with the PD-1 and B7.1 (CD80) receptors on immune cells. This blockade releases the "brakes" on the immune system, particularly on T cells, restoring their ability to recognize and attack tumor cells. Developed by Jiangsu Hengrui Medicine, it is approved in China and is in global clinical trials for various cancers, most notably in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), where it has demonstrated significant survival benefits.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.